-
1
المؤلفون: Claudia Schwarz, Gloria S. Benson, Nora Horn, Katharina Wurdack, Ulrike Grittner, Ralph Schilling, Stefanie Märschenz, Theresa Köbe, Sebastian J. Hofer, Christoph Magnes, Slaven Stekovic, Tobias Eisenberg, Stephan J. Sigrist, Dietmar Schmitz, Miranka Wirth, Frank Madeo, Agnes Flöel
المساهمون: Institute for Molecular Medicine Finland
المصدر: JAMA network open 5(5), e2213875 (2022). doi:10.1001/jamanetworkopen.2022.13875
مصطلحات موضوعية: drug therapy [Cognitive Dysfunction], Spermidine, pharmacology [Spermidine], Cognition, Animals, Humans, Cognitive Dysfunction, ddc:610, BRAIN, Aged, RISK, Inflammation, DEMENTIA, physiology [Cognition], 3112 Neurosciences, therapeutic use [Spermidine], Neurodegenerative Diseases, General Medicine, IMPAIRMENT, PATTERN, Dietary Supplements, TASK, AUTOPHAGY, Female, Function and Dysfunction of the Nervous System, Biomarkers, POLYAMINE INTAKE
وصف الملف: application/pdf
-
2Psychotherapeutic interventions in individuals at risk for Alzheimer’s dementia: a systematic review
المؤلفون: Ayda Rostamzadeh, Anna Kahlert, Franziska Kalthegener, Frank Jessen
المصدر: Alzheimer’s Research & Therapy, Vol 14, Iss 1, Pp 1-20 (2022)
Alzheimer's Research & Therapy
Alzheimer's research & therapy 14(1), 18 (2022). doi:10.1186/s13195-021-00956-8مصطلحات موضوعية: drug therapy [Cognitive Dysfunction], Alzheimer’s dementia, Cognitive Neuroscience, Neurosciences. Biological psychiatry. Neuropsychiatry, Review, Anxiety, Alzheimer Disease, Individuals at risk, drug therapy [Alzheimer Disease], Humans, Cognitive Dysfunction, ddc:610, RC346-429, Life Style, Prevention, Mild cognitive impairment, Psychotherapy, Neurology, Quality of Life, Subjective cognitive decline, Neurology. Diseases of the nervous system, Neurology (clinical), Psychoeducation, Alzheimer’s disease, RC321-571
-
3
المؤلفون: Ingo Kilimann, Diana Wucherer, Till Ittermann, Henry Völzke, Robin Bülow, Wolfgang Hoffmann, Hans Jörgen Grabe, Katharina Wittfeld, Stefan Johannes Teipel
المصدر: GeroScience 44(3), 1715-1726 (2022). doi:10.1007/s11357-021-00497-w
مصطلحات موضوعية: Aged, 80 and over, drug therapy [Cognitive Dysfunction], diagnostic imaging [Hippocampus], Male, Aging, Cholinergic Agents, diagnostic imaging [Cognitive Dysfunction], chemically induced [Cognitive Dysfunction], Medication, Hippocampus, Cholinergic Antagonists, adverse effects [Cholinergic Antagonists], Cognitive impairment, therapeutic use [Cholinergic Agents], Humans, Cognitive Dysfunction, Dementia, Female, ddc:610, Geriatrics and Gerontology, Alzheimer’s disease, Aged
-
4
المؤلفون: Jens Bohlken, Oliver Peters, Karel Kostev
المصدر: Journal of Alzheimer's disease 86(2), 703-709 (2022). doi:10.3233/JAD-215348
مصطلحات موضوعية: drug therapy [Cognitive Dysfunction], Male, epidemiology [Cognitive Dysfunction], therapeutic use [Plant Extracts], epidemiology [Dementia], Ginkgo biloba extract, mild cognitive impairment, Outpatients, mental disorders, Humans, Cognitive Dysfunction, ddc:610, Aged, Retrospective Studies, Plant Extracts, General Neuroscience, Incidence, Ginkgo biloba, drug therapy [Dementia], General Medicine, outpatients, Psychiatry and Mental health, Clinical Psychology, Prescriptions, Female, Dementia, Geriatrics and Gerontology, Phytotherapy
-
5
المؤلفون: Damiana, Scuteri, Giacinto, Bagetta, Pierluigi, Nicotera
المصدر: Current opinion in pharmacology 65, 102237 (2022). doi:10.1016/j.coph.2022.102237
مصطلحات موضوعية: drug therapy [Cognitive Dysfunction], Pharmacology, Cognition, ddc:340, Drug Discovery, Humans, Cognitive Dysfunction, Dementia, drug therapy [Dementia]
-
6
المصدر: Neuroscience letters 760, 136044 (2021). doi:10.1016/j.neulet.2021.136044
مصطلحات موضوعية: drug therapy [Cognitive Dysfunction], physiopathology [Cognitive Dysfunction], drug effects [Hippocampus], pharmacology [Lithium Compounds], Prodromal Symptoms, Neuropsychological Tests, physiopathology [Alzheimer Disease], Hippocampus, etiology [Cognitive Dysfunction], Lithium treatment, Alzheimer Disease, drug therapy [Alzheimer Disease], therapeutic use [Lithium Compounds], Humans, Cognitive Dysfunction, ddc:610, diagnosis [Alzheimer Disease], Mild cognitive impairment, complications [Alzheimer Disease], Neuroprotection, cerebrospinal fluid [Biomarkers], diagnosis [Cognitive Dysfunction], physiopathology [Hippocampus], Disease Progression, Lithium Compounds, Alzheimer’s disease, Biomarkers
-
7
المؤلفون: W. Maier, J. Kornhuber, L. K. Joachim, Christopher F. Bauer, Oliver Peters, Isabella Heuser, Jens Wiltfang, Lutz Frölich, E. Rüther
المصدر: The journal of prevention of Alzheimer's disease 5(3), 202-206 (2018). doi:10.14283/jpad.2018.5
مصطلحات موضوعية: Male, Oncology, Neurology, pathology [Cognitive Dysfunction], cerebrospinal fluid [Amyloid beta-Peptides], Neuropsychological Tests, therapeutic use [Galantamine], Hippocampus, law.invention, 0302 clinical medicine, Randomized controlled trial, law, Activities of Daily Living, Medicine, Cognitive decline, Randomized Controlled Trials as Topic, adverse effects [Memantine], Amygdala, amyloid beta-protein (1-42), Magnetic Resonance Imaging, 3. Good health, Cognitive test, cerebrospinal fluid [Cognitive Dysfunction], cerebrospinal fluid [Biomarkers], pathology [Amygdala], psychology [Randomized Controlled Trials as Topic], Disease Progression, Biomarker (medicine), Female, medicine.drug, drug therapy [Cognitive Dysfunction], medicine.medical_specialty, Clinical Dementia Rating, therapeutic use [Memantine], Neuroimaging, tau Proteins, 03 medical and health sciences, Double-Blind Method, Memantine, Internal medicine, mental disorders, Galantamine, Humans, Cognitive Dysfunction, ddc:610, cerebrospinal fluid [Peptide Fragments], Amyloid beta-Peptides, business.industry, Peptide Fragments, 030227 psychiatry, pathology [Hippocampus], Withholding Treatment, cerebrospinal fluid [tau Proteins], Observational study, adverse effects [Galantamine], business, Biomarkers, 030217 neurology & neurosurgery
-
8
المؤلفون: Jens Wiltfang, Claudia Bartels, Silke Schicktanz, Anna Kögel, Mark Schweda, Michael Pentzek, Anja Schneider
المصدر: Journal of Alzheimer's disease 78(3), 1137-1148 (2020). doi:10.3233/JAD-200794
مصطلحات موضوعية: Male, Disease, cerebrospinal fluid [Amyloid beta-Peptides], 0302 clinical medicine, Cerebrospinal fluid, Germany, statistics & numerical data [Psychiatry], Surveys and Questionnaires, Cognitive decline, Practice Patterns, Physicians', Phosphorylation, Cognitive impairment, Psychiatry, 0303 health sciences, General Neuroscience, General Medicine, Middle Aged, 3. Good health, cerebrospinal fluid [Alzheimer Disease], cerebrospinal fluid [Cognitive Dysfunction], Psychiatry and Mental health, Clinical Psychology, Neurology, cerebrospinal fluid [Biomarkers], Disease Progression, Biomarker (medicine), biomarker, Female, Alzheimer’s disease, Adult, drug therapy [Cognitive Dysfunction], medicine.medical_specialty, statistics & numerical data [Neurology], tau Proteins, 03 medical and health sciences, Diagnostic Self Evaluation, mild cognitive impairment, surveys, Alzheimer Disease, Internal medicine, Physicians, mental disorders, medicine, Dementia, Humans, Cognitive Dysfunction, ddc:610, cerebrospinal fluid [Peptide Fragments], Clinical care, Pathological, 030304 developmental biology, Amyloid beta-Peptides, business.industry, prediction, questionnaires, medicine.disease, Peptide Fragments, Cross-Sectional Studies, statistics & numerical data [Practice Patterns, Physicians'], diagnosis [Cognitive Dysfunction], cerebrospinal fluid [tau Proteins], Geriatrics and Gerontology, subjective cognitive decline, business, 030217 neurology & neurosurgery, Biomarkers
-
9
المؤلفون: Mikael Simons, Ludovico Cantuti-Castelvetri, Florian Raabe, Moritz J. Rossner, Andrea Schmitt, Lenka Slapakova, Peter Falkai
المصدر: Cells 8(12), 1496-(2019). doi:10.3390/cells8121496
Cellsمصطلحات موضوعية: cognition, 0301 basic medicine, drug therapy [Cognitive Dysfunction], Postmortem studies, Interneuron, pathology [Cognitive Dysfunction], drug therapy [Schizophrenia], oligodendrocytes, drug effects [Oligodendroglia], Review, interneuron, Disease, Biology, metabolism [Oligodendroglia], 03 medical and health sciences, Myelin, metabolism [Cognitive Dysfunction], 0302 clinical medicine, ddc:570, medicine, Animals, Humans, drug effects [Neurons], pathology [Neurons], Cognitive Dysfunction, Induced pluripotent stem cell, pathology [Schizophrenia], Neurons, treatment, Cognition, Cell Differentiation, General Medicine, Oligodendrocyte, schizophrenia, myelin, Oligodendroglia, 030104 developmental biology, medicine.anatomical_structure, metabolism [Neurons], pathology [Oligodendroglia], metabolism [Schizophrenia], Neuron, pluripotent stem cells, Neuroscience, 030217 neurology & neurosurgery
-
10
المؤلفون: Dan Liu, Yujia Zhao, Huanhuan Huang, Joshua D. Rosenblat, Roger S. McIntyre, Hui Zhou, Bing Cao
المصدر: Neuroscience letters 686, 10-16 (2018). doi:10.1016/j.neulet.2018.08.038
مصطلحات موضوعية: drug therapy [Cognitive Dysfunction], 0301 basic medicine, Oncology, medicine.medical_specialty, Subgroup analysis, tau Proteins, cerebrospinal fluid [Amyloid beta-Peptides], Disease, Cochrane Library, 03 medical and health sciences, 0302 clinical medicine, Alzheimer Disease, Internal medicine, drug therapy [Alzheimer Disease], Medicine, Dementia, Humans, Cognitive Dysfunction, ddc:610, cerebrospinal fluid [Peptide Fragments], Receptors, Immunologic, Amyloid beta-Peptides, Membrane Glycoproteins, TREM2 protein, human, business.industry, TREM2, General Neuroscience, diagnosis [Alzheimer Disease], Clinical course, medicine.disease, Peptide Fragments, cerebrospinal fluid [Alzheimer Disease], cerebrospinal fluid [Cognitive Dysfunction], 030104 developmental biology, cerebrospinal fluid [Biomarkers], cerebrospinal fluid [tau Proteins], Meta-analysis, Case-Control Studies, Disease Progression, cerebrospinal fluid [Membrane Glycoproteins], business, 030217 neurology & neurosurgery, Biomarkers, Cohort study
-
11
المؤلفون: Bartels, Claudia, Wagner, Michael, Wolfsgruber, Steffen, Ehrenreich, Hannelore, Schneider, Anja, Initiative, Alzheimer’s Disease Neuroimaging
المصدر: The American journal of psychiatry 175(3), 232-241 (2018). doi:10.1176/appi.ajp.2017.17040404
مصطلحات موضوعية: 0301 basic medicine, drug therapy [Cognitive Dysfunction], medicine.medical_specialty, Serotonin reuptake inhibitor, etiology [Alzheimer Disease], Disease, Kaplan-Meier Estimate, Citalopram, prevention & control [Alzheimer Disease], behavioral disciplines and activities, 03 medical and health sciences, 0302 clinical medicine, Alzheimer Disease, Risk Factors, mental disorders, complications [Depression], medicine, Humans, Alzheimer s dementia, Cognitive Dysfunction, ddc:610, drug therapy [Depression], Cognitive impairment, Psychiatry, Depression (differential diagnoses), Aged, Depression, therapeutic use [Selective Serotonin Reuptake Inhibitors], therapeutic use [Serotonin Uptake Inhibitors], 3. Good health, therapeutic use [Citalopram], Psychiatry and Mental health, 030104 developmental biology, Serotonin Uptake Inhibitors, Psychology, complications [Cognitive Dysfunction], 030217 neurology & neurosurgery, Geriatric psychiatry, Selective Serotonin Reuptake Inhibitors, medicine.drug, Alzheimer's Disease Neuroimaging Initiative
-
12
المؤلفون: Teipel, Stefan J, Cavedo, Enrica, Hampel, Harald, Group, Hippocampus Study, Godefroy, O., Deramond, H., Etcharry Bouyx, F., Pasco Papon, A., Dartigues, Jf, Allard, M., Rouaud, O., Ricolfi, F., Grothe, Michel J, Moreaud, O., Krainik, A., Pasquier, F., Bomboi, S., Delmaire, C., Couratier, P., Maubon, A., Vighetto, A., Croisile, B., Louis-Tisserand, G., Lista, Simone, Ceccaldi, M., Girard, N., Michel, B., Peretti, Mp, Touchon, J., Bonafe, A., Benetos, A., Barroche, G., Bracard, S., Vercelletto, M., Galluzzi, Samantha, Calvier Auffray, E., Robert, P., Chanalet, S., Dubois, B., Hampel, H., Dormont, D., Lehericy, S., Hugon, J., Pancrazi, M. P., Reizine, D., Colliot, Olivier, Gil, R., Vandermarcq, P., Novella, J. L., Pierot, L., Belliard, S., Carsin, M., Martinaud, O., Gerardin, E., Laurent, B., Barral, Fg, Chupin, Marie, Sellal, F., Ousset, Pj, Puel, M., Ait Ameur, A., Dumas, H., Mondon, K., Cottier, Jp, Bakardjian, Hovagim, Dormont, Didier, Dubois, Bruno
المساهمون: University of Rostock, Université Pierre et Marie Curie - Paris 6 (UPMC), German Research Center for Neurodegenerative Diseases - Deutsches Zentrum für Neurodegenerative Erkrankungen (DZNE), Institut de la Mémoire et de la Maladie d'Alzheimer [CHU Pitié-Salpétriêre] (IM2A), Université Pierre et Marie Curie - Paris 6 (UPMC)-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Institut du Cerveau et de la Moëlle Epinière = Brain and Spine Institute (ICM), Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Centre National de la Recherche Scientifique (CNRS), Algorithms, models and methods for images and signals of the human brain (ARAMIS), Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut du Cerveau et de la Moëlle Epinière = Brain and Spine Institute (ICM), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Centre National de la Recherche Scientifique (CNRS)-Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Centre National de la Recherche Scientifique (CNRS)-Inria de Paris, Institut National de Recherche en Informatique et en Automatique (Inria)-Institut National de Recherche en Informatique et en Automatique (Inria), Service de Neuroradiologie [CHU Pitié-Salpêtrière], CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS)-Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS)-Inria de Paris, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), CHU Amiens-Picardie, Laboratoire de Neurosciences Fonctionnelles et Pathologies - UR UPJV 4559 (LNFP), Université de Picardie Jules Verne (UPJV), Hippocampus Study Group, Institut de la Mémoire et de la Maladie d'Alzheimer [Paris] (IM2A), Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-CHU Pitié-Salpêtrière [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-CHU Pitié-Salpêtrière [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Inria de Paris, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Inria de Paris, Service de neuroradiologie diagnostique et fonctionnelle [CHU Pitié-Salpêtrière], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU)
المصدر: Neuropharmacology
Neuropharmacology, Elsevier, 2016, 108, pp.128-35
Neuropharmacology, 2016, 108, pp.128-35. ⟨10.1016/j.neuropharm.2016.02.005⟩
Neuropharmacology 108, 128-135 (2016). doi:10.1016/j.neuropharm.2016.02.005
HALمصطلحات موضوعية: 0301 basic medicine, Male, psychology [Alzheimer Disease], Cross-sectional study, [SDV.IB.IMA]Life Sciences [q-bio]/Bioengineering/Imaging, [SDV.NEU.NB]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Neurobiology, diagnostic imaging [Cognitive Dysfunction], 0302 clinical medicine, Piperidines, drug therapy [Alzheimer Disease], Donepezil, Cognitive decline, therapeutic use [Indans], Nootropic Agents, therapeutic use [Piperidines], Aged, 80 and over, therapeutic use [Nootropic Agents], Cognition, Magnetic Resonance Imaging, Treatment Outcome, Predictive value of tests, [INFO.INFO-TI]Computer Science [cs]/Image Processing [eess.IV], Indans, Disease Progression, Female, psychology [Cognitive Dysfunction], Alzheimer's disease, Psychology, [SPI.SIGNAL]Engineering Sciences [physics]/Signal and Image processing, medicine.drug, Clinical psychology, drug therapy [Cognitive Dysfunction], medicine.medical_specialty, trends [Magnetic Resonance Imaging], Prodromal Symptoms, Placebo, 03 medical and health sciences, Cellular and Molecular Neuroscience, Double-Blind Method, Alzheimer Disease, Predictive Value of Tests, Internal medicine, medicine, [INFO.INFO-IM]Computer Science [cs]/Medical Imaging, Humans, Cognitive Dysfunction, ddc:610, Aged, Pharmacology, [INFO.INFO-CV]Computer Science [cs]/Computer Vision and Pattern Recognition [cs.CV], medicine.disease, Clinical trial, 030104 developmental biology, Cross-Sectional Studies, diagnostic imaging [Alzheimer Disease], 030217 neurology & neurosurgery, Follow-Up Studies
-
13
المؤلفون: Samantha Galluzzi, Christine Born, Thomas Meindl, Simone Lista, Frank Faltraco, Arun L.W. Bokde, Maximilian F. Reiser, Harald Hampel, Enrica Cavedo, Patricia Lopez-Bayo, Stefan J. Teipel, Hans-Jürgen Möller, Bruno Dubois
المصدر: Psychiatry research 249, 84-90 (2016). doi:10.1016/j.pscychresns.2016.01.018
مصطلحات موضوعية: Male, physiopathology [Cognitive Dysfunction], drug therapy [Amnesia], Pilot Projects, Visual system, physiopathology [Brain], Brain mapping, methods [Brain Mapping], 0302 clinical medicine, methods [Magnetic Resonance Imaging], Attention, Rivastigmine, Aged, 80 and over, Brain Mapping, medicine.diagnostic_test, drug effects [Facial Recognition], 05 social sciences, Brain, Cognition, Middle Aged, Magnetic Resonance Imaging, Psychiatry and Mental health, Neuroprotective Agents, drug effects [Brain], Female, medicine.symptom, Psychology, Facial Recognition, medicine.drug, drug therapy [Cognitive Dysfunction], medicine.medical_specialty, Neuroscience (miscellaneous), Amnesia, Placebo, behavioral disciplines and activities, 050105 experimental psychology, pharmacology [Rivastigmine], 03 medical and health sciences, Physical medicine and rehabilitation, Double-Blind Method, medicine, drug effects [Attention], Humans, Cognitive Dysfunction, Visual Pathways, 0501 psychology and cognitive sciences, Radiology, Nuclear Medicine and imaging, ddc:610, diagnostic imaging [Brain], drug effects [Visual Pathways], Aged, pharmacology [Neuroprotective Agents], Magnetic resonance imaging, physiopathology [Amnesia], Functional magnetic resonance imaging, Neuroscience, 030217 neurology & neurosurgery
-
14A combination of galantamine and memantine modifies cognitive function in subjects with amnestic MCI
المؤلفون: Stefan Wellek, A. Fesche, Stefan J. Teipel, Isabella Heuser, Frank Jessen, D. Lorenz, H.-J. Möller, Lutz Frölich, Christian Luckhaus, E. Rüther, Johannes Pantel, Klaus Schmidtke, Michael Hüll, Johannes Schröder, Johannes Kornhuber, Oliver Peters, Wolfgang Maier, Hermann-Josef Gertz, Robert Perneczky, Holger Jahn
المصدر: The journal of nutrition, health & aging 16(6), 544-548 (2012). doi:10.1007/s12603-012-0062-8
مصطلحات موضوعية: Male, physiopathology [Cognitive Dysfunction], Medicine (miscellaneous), Audiology, therapeutic use [Galantamine], adverse effects [Cholinesterase Inhibitors], etiology [Cognitive Dysfunction], Cohort Studies, Cognition, Germany, Cognitive impairment, Episodic memory, antagonists & inhibitors [Receptors, N-Methyl-D-Aspartate], Nootropic Agents, Nutrition and Dietetics, therapeutic use [Nootropic Agents], Memantine, adverse effects [Memantine], Middle Aged, prevention & control [Dementia], drug effects [Cognition], Early Termination of Clinical Trials, Disease Progression, Drug Therapy, Combination, Female, medicine.drug, drug therapy [Cognitive Dysfunction], medicine.medical_specialty, therapeutic use [Memantine], behavioral disciplines and activities, physiopathology [Alzheimer Disease], Receptors, N-Methyl-D-Aspartate, Dementia disorders, therapeutic use [Cholinesterase Inhibitors], Double-Blind Method, Alzheimer Disease, mental disorders, medicine, Galantamine, Dementia, etiology [Amnesia], Humans, Cognitive Dysfunction, ddc:610, Aged, adverse effects [Nootropic Agents], Psychiatric Status Rating Scales, business.industry, medicine.disease, nervous system diseases, Multicenter study, prevention & control [Amnesia], adverse effects [Drug Therapy, Combination], Amnesia, Cholinesterase Inhibitors, Geriatrics and Gerontology, business, adverse effects [Galantamine], human activities
-
15
المؤلفون: Guido Straten, Christoph Laske, Thomas Gasser, Hans Basun, Thomas Leyhe, Ralf Saur, Peter Annas
المصدر: Current Alzheimer research 8(8), 853-859 (2011). doi:10.2174/156720511798192754
مصطلحات موضوعية: Male, Neurology, Lithium (medication), pharmacology [Lithium Compounds], Neuropsychological Tests, Cerebrospinal fluid, Neurotrophic factors, Antimanic Agents, Glial cell line-derived neurotrophic factor, drug therapy [Alzheimer Disease], pharmacology [Sulfates], cerebrospinal fluid [Glial Cell Line-Derived Neurotrophic Factor], Single-Blind Method, Aged, 80 and over, biology, Sulfates, Middle Aged, therapeutic use [Neuroprotective Agents], cerebrospinal fluid [Alzheimer Disease], cerebrospinal fluid [Cognitive Dysfunction], Neuroprotective Agents, Lithium Compounds, Female, medicine.symptom, Neurotrophin, medicine.drug, drug therapy [Cognitive Dysfunction], medicine.medical_specialty, lithium sulfate, blood [Glial Cell Line-Derived Neurotrophic Factor], Placebo, blood [Alzheimer Disease], Alzheimer Disease, Internal medicine, medicine, Humans, Cognitive Dysfunction, ddc:610, Glial Cell Line-Derived Neurotrophic Factor, Aged, business.industry, pharmacology [Neuroprotective Agents], Endocrinology, Mechanism of action, therapeutic use [Antimanic Agents], blood [Cognitive Dysfunction], biology.protein, Neurology (clinical), business, pharmacology [Antimanic Agents]